Advanced search
Publication Cover
Future Virology Volume 7, 2012 - Issue 5
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Review

From Virus-like Particles to Engineered Exosomes for a New Generation of Vaccines

Maurizio FedericoNational AIDS Center, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161Rome, Italy. ▪ Tel.: +39 06 49906073 ▪ Fax: +39 06 49903002 ▪ [email protected]View further author information
Pages 473-482 | Published online: 17 May 2012

References

  • Roy P , NoadR. Virus-like particles as a vaccine delivery system: myths and facts. Adv. Exp. Med. Biol.655 , 145–158 (2009).
  • Herbst-Kralovetz M , MasonHS, ChenQ. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines9(3) , 299–307 (2010).
  • El-Kamary SS , PasettiMF, MendelmanPM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11) , 1649–1658 (2010).
  • Velasquez LS , ShiraS, BertaAN et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29(32) , 5221–5231 (2011).
  • Walpita P , BarrJ, ShermanM, BaslerCF, WangL. Vaccine potential of Nipah virus-like particles. PLoS One6(4) , E18437 (2011).
  • McGinnes LW , PantuaH, LaliberteJP, GravelKA, JainS, MorrisonTG. Assembly and biological and immunological properties of Newcastle disease virus-like particles. J. Virol.84(9) , 4513–4523 (2010).
  • Lee DH , ParkJK, LeeYN et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine 29(23) , 4003–4007 (2011).
  • Wu CY , YehYC, YangYC et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 5(3) , E9784 (2010).
  • Quan FS , VunnavaA, CompansRW, KangSM. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One5(2) , E9161 (2010).
  • Pushko P , PearceMB, AhmadA et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29(35) , 5911–5918 (2011).
  • Khurana S , WuJ, VermaN. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J. Virol.85(21) , 10945–10954 (2011).
  • Tang XC , LuHR, RossTM. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol.24(4) , 311–319 (2011).
  • Warfield KL , AmanMJ. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis.204(Suppl. 3) , S1053–S1059 (2011).
  • Ruiss R , JochumS, WannerG, ReisbachG, HammerschmidtW, ZeidlerR. A virus-like particle-based Epstein–Barr virus vaccine. J. Virol.85(24) , 13105–13113 (2011).
  • Ohtaki N , TakahashiH, KanekoK et al. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 28(40) , 6588–6596 (2010).
  • Zhang S , LiangM, GuW et al. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol. J. 8 , 333 (2011).
  • Akahata W , YangZY, AndersenH et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat. Med. 16(3) , 334–338 (2010).
  • Quan FS , KimY, LeeS et al. Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice. J. Infect. Dis. 204(7) , 987–995 (2011).
  • McGinnes LW , GravelKA, FinbergRW et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J. Virol. 85(1) , 366–377 (2011).
  • Liu YV , MassareMJ, BarnardDL et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29(38) , 6606–6613 (2011).
  • Ma Y , LiJ. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J. Virol.85(6) , 2942–2952 (2011).
  • Klamp T , SchumacherJ, HuberG et al. Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Res. 71(2) , 516–527 (2011).
  • Chackerian B . Virus-like particle based vaccines for Alzheimer disease. Hum. Vaccin.6(11) , 926–930 (2010).
  • Tumban E , PeabodyJ, PeabodyDS, ChackerianB. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One6(8) , E23310 (2011).
  • Röhn TA , RalveniusWT, PaulJ et al. A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. J. Immunol. 186(3) , 1769–1780 (2011).
  • Caldeira Jdo C , MedfordA, KinesRC et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28(27) , 4384–4393 (2010).
  • Spohn G , JenningsGT, MartinaBE et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J. 7 , 146 (2010).
  • Brown SD , FiedlerJD, FinnMG. Assembly of hybrid bacteriophage Qβ virus-like particles. Biochemistry48(47) , 11155–11157 (2009).
  • Tan M , HuangP, XiaM et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J. Virol. 85(2) , 753–764 (2010).
  • Middelberg AP , Rivera-HernandezT, WibowoN et al. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29(41) , 7154–7162 (2011).
  • Montefiori DC , SafritJT, LydySL et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol. 75(13) , 5879–5890 (2001).
  • Deml L , KratochwilG, OsterriederN, KnüchelR, WolfH, WagnerR. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein–Barr virus gp220/350-derived transmembrane domain. Virology235(1) , 10–25 (1997).
  • Kattenbeck B , von Poblotzki A, Rohrhofer A, Wolf H, Modrow S. Inhibition of human immunodeficiency virus type 1 particle formation by alterations of defined amino acids within the C terminus of the capsid protein. J. Gen. Virol.78(Pt 10) , 2489–2496 (1997).
  • Yao XJ , KobingerG, DandacheS, RougeauN, CohenE. HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect. Gene Ther.6(9) , 1590–1599 (1999).
  • McDonald D , VodickaMA, LuceroG et al. Visualization of the intracellular behavior of HIV in living cells. J. Cell. Biol. 159(3) , 441–452 (2002).
  • Cavrois M , De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol.20(11) , 1151–1154 (2002).
  • Peretti S , SchiavoniI, PuglieseK, FedericoM. Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol. Ther.12(6) , 1185–1196 (2005).
  • Di Bonito P , GrassoF, MochiS et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395(1) , 45–55 (2009).
  • Sistigu A , BracciL, ValentiniM et al. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine 29(18) , 3465–3475 (2011).
  • Buonaguro L , ViscianoML, TorneselloML, TagliamonteM, BiryahwahoB, BuonaguroFM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol.79(11) , 7059–7067 (2005).
  • Garrone P , FluckigerAC, MangeotPE et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3(94) , 94ra71 (2011).
  • Yewdell JW , NorburyCC, BenninkJR. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol.73 , 1–77 (1999).
  • Marsac D , LoiratD, PetitC, SchwartzO, MichelML. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol.76 , 7544–7553 (2002).
  • Buseyne F , Le Gall S, Boccaccio C et al. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med.7(3) , 344–349 (2001).
  • Segura MM , GarnierA, DurocherY, AnsorgeS, KamenA. New protocol for lentiviral vector mass production. Methods Mol. Biol.614 , 39–52 (2010).
  • György B , SzabóTG, PásztóiM et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol. Life Sci. 68(16) , 2667–2688 (2011).
  • Booth AM , FangY, FallonJK, YangJM, HildrethJE, GouldSJ. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J. Cell. Biol.172(6) , 923–935 (2006).
  • Mathivanan S , JiH, SimpsonRJ. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics73(10) , 1907–1920 (2010).
  • Skog J , WürdingerT, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol.10(12) , 1470–1476 (2008).
  • Gibbings DJ , CiaudoC, ErhardtM, VoinnetO. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol.11(9) , 1143–1149 (2009).
  • Tan A , De La Peña H, Seifalian AM. The application of exosomes as a nanoscale cancer vaccine. Int. J. Nanomed.5 , 889–900 (2010).
  • Chaput N , ThéryC. Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol.33(5) , 419–440 (2010).
  • Bhatnagar S , SchoreyJS. Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory. J. Biol. Chem.282(35) , 25779–25789 (2007).
  • Yang C , KimSH, BiancoNR, RobbinsPD. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS One6(8) , E22517 (2011).
  • Andreola G , RivoltiniL, CastelliC. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med.195(10) , 1303–1316 (2002).
  • Szajnik M , CzystowskaM, SzczepanskiMJ, MandapathilM, WhitesideTL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One5(7) , E11469 (2010).
  • Ashiru O , BoutetP, Fernández-MessinaL et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 70(2) , 481–489 (2010).
  • Muratori C , CavallinLE, KrätzelK et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6(3) , 218–230 (2009).
  • Flanagan J , MiddeldorpJ, SculleyT. Localization of the Epstein–Barr virus protein LMP 1 to exosomes. J. Gen. Virol.84(Pt 7) , 1871–1879 (2003).
  • Keryer-Bibens C , Pioche-DurieuC, VillemantC et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6 , 283 (2006).
  • Kim SH , LechmanER, BiancoN et al. Exosomes derived from IL-10 treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 174(10) , 6440–6448 (2005).
  • Kim SH , BiancoN, Menon et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosoppressive. Mol. Ther.13(2) , 289–300 (2006).
  • Xie Y , BaiO, ZhangH, LiW, XiangJ. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity. Cancer Biother. Radiopharm.25(1) , 21–28 (2010).
  • Dai S , WeiD, WuZ et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 16(4) , 782–790 (2008).
  • Escudier B , DorvalT, ChaputN et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first Phase I clinical trial. J. Transl. Med. 3(1) , 10 (2005).
  • Morse MA , GarstJ, OsadaT et al. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3(1) , 9 (2005).
  • Nguyen DG , BoothA, GouldSJ, HildrethJE. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J. Biol. Chem.278(52) , 52347–52354 (2003).
  • Mori Y , KoikeM, MoriishiE et al. Human herpesvirus-6 induces MVB formation, and virus egress occurs by an exosomal release pathway. Traffic 9(10) , 1728–1742 (2008).
  • Usami Y , PopovS, PopovaE, InoueM, WeissenhornW, G Göttlinger H. The ESCRT pathway and HIV-1 budding. Biochem. Soc. Trans.37(Pt 1) , 181–184 (2009).
  • Chazal N , GerlierD. Virus entry, assembly, budding, and membrane rafts. Microbiol. Mol. Biol. Rev.67(2) , 226–237 (2003).
  • Simons K , SampaioJL. Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol.3(10) , A004697 (2011).
  • de Gassart A , GeminardC, FevrierB, RaposoG, VidalM. Lipid raft-associated protein sorting in exosomes. Blood102(13) , 4336–4344 (2003).
  • Gould SJ , BoothAM, HildrethJE. The Trojan exosome hypothesis. Proc. Natl Acad. Sci. USA100(19) , 10592–10597 (2003).
  • Fang Y , WuN, GanX, YanW, MorrellJC, GouldSJ. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol.5(6) , E158 (2007).
  • Lenassi M , CagneyG, LiaoM et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 11(1) , 110–122 (2010).
  • Foster JL , DenialSJ, TempleBR, GarciaJV. Mechanisms of HIV-1 Nef function and intracellular signaling. J. Neuroimmune Pharmacol.6(2) , 230–246 (2011).
  • Brügger B , GlassB, HaberkantP, LeibrechtI, WielandFT, KräusslichHG. The HIV lipidome: a raft with an unusual composition. Proc. Natl Acad. Sci. USA103(8) , 2641–2646 (2006).
  • Parolini I , FedericiC, RaggiC et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284(49) , 34211–34222 (2009).
  • Feng D , ZhaoWL, YeYY et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic 11(5) , 675–687 (2010).
  • Lamparski HG , Metha-DamaniA, YaoJY et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods 270(2) , 211–226 (2002).
  • Krishnamachari Y , GearySM, LemkeCD, SalemAK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res.28(2) , 215–236 (2011).
  • Ruiss R , JochumS, MocikatR, HammerschmidtW, ZeilderR. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells-A new option for the treatment of B-CLL. PLoS One6(10) , E25294 (2011).
  • Zhang J , ZhangY, LuoC, XiaY, ChenH, WuX. Glycosyl-phosphatidylinositol-anchored interleukin-2 expressed on tumor-derived exosomes induces antitumor immune response in vitro. Tumori96(3) , 452–459 (2010).
  • Zhang Y , LuoCL, HeBC, ZhangJM, ChengG, WuHX. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int. J. Oncol.36(1) , 133–140 (2010).
  • Delcayre A , EstellesA, SperindeJ. Exosome display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol. Dis.35(2) , 158–168 (2005).
  • Hartman ZC , WeiJ, GlassOK et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 29(50) , 9361–9367 (2011).
  • Xiu F , CaiZ, YangY, WangX, WangJ, CaoX. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J. Mol. Med.85(5) , 511–521 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.